IGFBP7 and cancer: We found that these two CpG sites in the IGFBP7 promoter are cancer-specifically methylated (Figure 5B) and strongly associated with both BRAFV600E (Wilcoxon rank-sum test, P value  = 2.0×10−10) and CIMP (P value  = 3.6×10−9) (Figure 5C).